BioMarin reports 3-year vosoritide growth data in hypochondroplasia and early BMN 333 findings in achondroplasia.
ENDO
Diazoxide choline showed sustained hyperphagia improvements in Prader-Willi syndrome after randomized withdrawal and retreatment.
Advertisement
Setmelanotide reduced BMI measures, fat mass, and hyperphagia scores in interim phase 2 Prader-Willi syndrome data.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA issues Warning Letter to SNOO Smart Sleeper maker over unauthorized sleep sacks, hospital bundle, and quality system failures
2
pCPA receives FDA Orphan Drug Designation for monoamine oxidase deficiency
3
Diazoxide choline data show durable hyperphagia gains in Prader-Willi syndrome
4
Setmelanotide shows interim phase 2 signals in Prader-Willi syndrome
5